SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending due to its strong community, active developer involvement, and upcoming utilities like staking. Community members are excited about the potential for burns and new contests, contributing to the bullish sentiment. The coin's consistent grinding and recent CEX listing are also driving interest in this Solana-based project.

Pyth Network is a decentralised oracle network designed to provide real-time financial market data to decentralised applications (dApps) across multiple blockchains. It allows developer to secure smart contracts with reliable, low-latency market data from institutional sources, and build apps with high-fidelity oracle feeds designed for mission-critical systems.

Pyth Network

Pyth Network is trending as the community discusses its potential, particularly its role in real-world asset (RWA) tokenization and its partnership with the U.S. Department of Commerce to provide economic data on-chain. Traders are also watching key resistance levels, anticipating the next leg up.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

$DOG.X is trending as the community rallies behind this Bitcoin-native meme coin launched via the Runes protocol, touting its fair distribution and strong ties to the Bitcoin network. Many see it as a successor to DOGE, with the potential to lead the meme coin space this cycle. The community emphasizes its unique position, providing utility to the Bitcoin network through miner fees.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending as community members discuss updated data from its HARMONi trial, which showed a survival benefit for Western patients with EGFR-mutated non-small cell lung cancer treated with ivonescimab plus chemotherapy. The data is spurring debate about the drug's potential impact on competitors like $IOVA and whether it could become a Keytruda competitor, with some speculating about a possible partnership announcement. Community sentiment is mixed, ranging from bullish long-term outlooks to concerns about data interpretation and potential short-term volatility.

ProShares Trust - ProShares Short Dow30 -1x Shares

ProShares Short Dow30

$DOG is trending as community members highlight its position as a Bitcoin-native meme coin with a fair launch and decentralized distribution. The community is actively discussing its strong cult-like following and potential for significant growth within the crypto space. Some proponents suggest it could rival other popular meme coins like DOGE and SHIB.

This platform is engineered to unlock the full potential of Real-World Assets (RWAs) by bringing them onto the XRP Ledger with unparalleled efficiency. Our purpose is to democratize access to high-value assets by providing a streamlined, end-to-end solution for tokenization. Functionally, we offer tools for asset verification, compliant legal wrapping, and the minting of RWA tokens. The project's core utility is twofold: for asset owners, it unlocks immediate liquidity and access to global capital markets; for investors, it offers fractional, transparent, and liquid access to investment classes like private equity and infrastructure bonds. We leverage the XRPL's native speed and built-in DEX to ensure low-cost transactions and instant settlement, setting a new standard for RWA interoperability and finance.

VOLT

VOLT ($XVM.X) is trending as community members discuss its potential integration with established platforms like XRP and its role in tokenizing real-world assets (RWA). Investors are trying to find the best place to purchase it. Many community members believe that it still has tremendous upside.

Sapien is an open protocol for sourcing verified human knowledge at scale. Its network of millions of contributors spans more than 100 countries, ranging from doctors and engineers to artists and students. Together they produce high-quality AI training data, validated through Sapien’s onchain Proof of Quality system. This ensures enterprises and AI developers can access trusted, human-in-the-loop data while transforming fragmented online work into a sustainable, reputation-based profession. Incentives across the network are powered by the $SAPIEN token, an ERC-20 asset on Base.

Sapien

Sapien (SAPIEN.X) is trending as the crypto community discusses its potential for significant gains and compares it to other recently successful tokens. Some users point to its chart setup and potential consolidation, while others speculate about price targets and its potential as an AI-driven project. The conversation also includes discussions about possible scams and whether it is too late to buy.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. It focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

IDYA is trending due to promising Phase 2 data for its darovasertib and crizotinib combination in metastatic uveal melanoma, as well as a successful FDA Type C meeting, potentially leading to accelerated approval. The community is focused on the drug's potential to become a practice-changing treatment, with analysts highlighting a large market opportunity and significant pipeline optionality. Several analysts have reiterated bullish ratings and increased price targets, reinforcing positive sentiment around the stock.

Gyrodyne LLC engages in the management of a portfolio of medical office and industrial properties. Its properties include Flowerfield, Port Jefferson Professional Park, Courtland Medical Center, and Grove. The company was founded by Peter James Papadakos in 1946 and is headquartered in St. James, NY.

Gyrodyne LLC

Gyrodyne is trending due to a recent land sale boosting its NAV, with investors focusing on its potential real estate value. The stock's low float is fueling speculation of a potential squeeze, with the community actively discussing entry points and breakout levels. Some traders are pointing to a potential breakout past the $15 mark, which could trigger a rally.

YUPFUN is a Solana-based meme and DeFi project that fuses viral meme culture with real decentralized finance utility. It aims to create a fun, community-driven ecosystem where users can trade, stake, and bridge tokens seamlessly across multiple liquidity pools and decentralized exchanges (DEXs) like BitStorage.finance Raydium, Orca, Meteora, PumpSwap, MintMe.com. YUPFUN isn't just about memes — it's about empowering the community with real ownership through fair launch mechanics, liquidity incentives, and cross-chain accessibility. The project also promotes creative engagement by encouraging users to create and share memes, art, and participate in community-driven events to grow the YUPFUN brand. With no VC backing, no private sales, and no hidden agendas, YUPFUN represents a true decentralized, permissionless movement blending entertainment with real blockchain functionality.

YUPFUN Token

YUPFUN.X is trending as the community believes it's primed for significant growth and widespread adoption. Positive sentiment is fueled by claims of increasing virality and strong holder enthusiasm. Traders are closely watching the charts, suggesting possible momentum-based strategies are in play.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Revvity, Inc. (RVTY) CEO Prahlad Singh acknowledged challenges to the company’s immunodiagnostics business in China, owing to changes in regulations, and warned of a pullback during the firm’s earnings call on Monday.The CEO stated that the company began experiencing challenges in its diagnostics business midway through the second quarter, due to a revised lab reimbursement policy tied to Diagnosis-Related Groups (DRGs), which affected the size of diagnostic panels ordered by physicians in the country.Healthcare providers are opting for fewer multiplex diagnostic products, the CEO said, while noting that this trend is likely to drive volume for single-plex tests.“For the remainder of the year, we are now expecting a fairly meaningful pullback in our immunodiagnostics business in China, which is incorporated into our updated outlook for the total company for the year,” Singh said. The immunodiagnostics business in China represents 6% of the company’s total revenue.Shares of the company slid 8% as of Monday afternoon, at the time of writing.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/RVTY">RVTY</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1358/124;" src="https://news.stocktwits-cdn.com/Screenshot_2025_07_28_at_1_30_31_PM_png_4f6a008503.webp" alt="RVTY's Sentiment Meter and Message Volume as of 1:30 p.m. ET on July 28, 2025 | Source: Stocktwits" width="1358" height="124"><figcaption>RVTY's Sentiment Meter and Message Volume as of 1:30 p.m. ET on July 28, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user opined that the drop in stock on Monday is an overreaction, and that it is being overly punished for a change in Chinese regulation.<stembedurl>https://stocktwits.com/Spartan2008/message/622689408</stembedurl>Yet another opined that the change in regulation applies to all companies in the space and that the company has sufficient cash on hand.<stembedurl>https://stocktwits.com/YouOnlyLiveTwice/message/622719140</stembedurl>For the full year 2025, the company has raised its revenue guidance to $2.84 billion to $2.88 billion, reflecting recent changes in foreign currency exchange rates and assuming 2% to 4% organic growth.The company also updated its adjusted earnings per share guidance to a range of $4.85 to $4.95, down from its previous guidance of $4.90 to $5.For the second quarter, the company’s revenue came in at $720 million, marking a 4% growth and exceeding an analyst estimate of $711.33 million, according to data from Fiscal AI.Adjusted earnings per share for the quarter came in at $1.18, compared to $1.22 in the corresponding period of 2024, but above an expected $1.14.RVTY stock is down by 14% this year and by about 24% over the past 12 months.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/cervomed-dementia-drug-slows-disease-progression-in-study/choeuj6R5xa">CervoMed Dementia Drug Slows Disease Progression In Study: Retail Loads Up On The Stock</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Revvity company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Revvity CEO Acknowledges Challenges In Immunodiagnostics Business In China: Retail Terms Stock Drop An ‘Overreaction’

Healthcare providers are opting for fewer multiplex diagnostic products, the CEO said, while noting that this trend is likely to drive volume for single-plex tests.

Equity

U.S. equities edged up in Monday’s midday trade after President Donald Trump announced the highly anticipated tariff deal with the European Union. Semiconductor stocks also benefited from reports that the Trump administration had temporarily halted restrictions on technology exports to China.The&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which mirrors the S&amp;P 500 index, up 0.04% at the time of writing, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ), which mirrors the Nasdaq, gained 0.32%.Here are the top stocks making the biggest moves in Monday’s midday trade:<a href="https://stocktwits.com/symbol/TSLA">Tesla Inc. (TSLA)</a>Tesla’s shares extended their surge from Friday and gained nearly 4% in midday trade on Monday after the company announced a $16.5 billion partnership with Samsung Electronics for semiconductor chips.<a href="https://stocktwits.com/symbol/TSLA">TSLA stock</a> is down 19% year-to-date.<a href="https://stocktwits.com/symbol/AMD">Advanced Micro Devices Inc.</a> (AMD),&nbsp;<a href="https://stocktwits.com/symbol/SMCI">Super Micro Computer Inc.</a> (SMCI)AMD stock surged to a fresh 52-week high on Monday, rising more than 4% after the U.S.-EU trade deal established “zero-for-zero” tariffs on semiconductor machinery.SMCI stock surged more than 7%, like some of its other semiconductor peers.Aiding the surge in semiconductor stocks on Monday is a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/a13ba438-3b43-46dd-b332-4b81b3644da0">report</a> by the Financial Times stating that the U.S. has temporarily halted restrictions on technology exports to China.<a href="https://stocktwits.com/symbol/AMD">AMD stock</a> is up more than 43% for the year, while the&nbsp;<a href="https://stocktwits.com/symbol/SMCI">SMCI stock</a> is up over 92%.<a href="https://stocktwits.com/symbol/NKE">Nike Inc. (NKE)</a>Nike saw its shares surge nearly 4% on Monday after analysts at JPMorgan&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nike-heads-toward-5-month-highs-after-jpmorgan-upgrade-retail-expects-stock-to-hit-90-mark/choesisR5xe">upgraded the stock</a> to ‘Overweight’ from ‘Neutral,’ citing a potential multi-year recovery.<a href="https://stocktwits.com/symbol/NKE">NKE stock</a> is up nearly 5% for the year.<a href="https://stocktwits.com/symbol/RVTY">Revvity Inc. (RVTY)</a>Revvity shares fell nearly 9% on Monday after the company lowered its earnings outlook for 2025 from $4.9 to $5 per share to $4.85 to $4.95 per share. The company cited a recent regulatory change in China regarding hospital laboratory reimbursement rules, which resulted in a reduction in the overall volumes of its products.<a href="https://stocktwits.com/symbol/RVTY">RVTY stock</a> is down nearly 15% for the year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/firefly-aerospace-fly-ipo-55-b-valuation/choeVfRR5Du">Firefly Aerospace IPO: Space Startup Aims For $5.5B Valuation As Market Debut Nears</a>

A bull statue and a bear statue stand outside the Frankfurt Stock Exchange on April 7, 2025 in Frankfurt, Germany

Tesla, AMD, SMCI, Nike, Revvity: Stocks Making The Biggest Moves Today

Tesla’s shares continued to rise on Monday, extending the surge from Friday after the company announced a $16.5 billion partnership with Samsung Electronics for semiconductor chips.

RVTY Posts Q2 Earnings & Sales Beat, Raises '25 Sales View 

Revvity's second-quarter results showcase strong growth in its Diagnostics business, along with recovery in Life Sciences segmental sales.

Revvity (RVTY) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for Revvity (RVTY) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Revvity (RVTY) Surpasses Q2 Earnings and Revenue Estimates

Revvity (RVTY) delivered earnings and revenue surprises of +3.51% and +1.27%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Why Revvity (RVTY) is Poised to Beat Earnings Estimates Again

Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Revvity Q2 Preview: Can Strong Segments Deliver an Earnings Beat?

RVTY is likely to see another earnings beat as Diagnostics momentum and Signals Software growth offset tariff headwinds.

Wall Street's Insights Into Key Metrics Ahead of Revvity (RVTY) Q2 Earnings

Beyond analysts' top-and-bottom-line estimates for Revvity (RVTY), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended June 2025.

GeneDx Holdings Corp. (WGS) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

GENEDX HOLDINGS (WGS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Revvity (RVTY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

Revvity (RVTY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. The firm operates through the following segments: Life Sciences and Diagnostics. The Life Sciences segment delivers innovative solutions to optimize workflows, boost productivity, and accelerate drug discovery and development. The Diagnostics segment provides instruments, reagents, assay platforms, and software to healthcare and research professionals, with a focus on reproductive health, immunodiagnostics, emerging market diagnostics, and applied genomics to enhance patient outcomes. Revvity was founded on April 19, 1937 and is headquartered in Waltham, MA.

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	$1.14	--	--	N/A
Q2 '25	$1.14	$1.18	3.40%	BEAT
Q1 '25	$0.95	$1.01	6.46%	BEAT
Q4 '24	$1.37	$1.42	3.77%	BEAT
Q3 '24	$1.13	$1.28	13.64%	BEAT

RVTY
Revvity Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest RVTY News

RVTY Revvity Inc.